Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Fozzatti, Laura ^a   Park, Jeong Won ^a   Zhao, Li ^a   Willingham, Mark C ^a   Cheng, Sheue yann ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE 3; MUTANT PROTEIN; PROTEIN BAX; PROTEIN P53; RECEPTOR INTERACTING PROTEIN 140; THYROID HORMONE RECEPTOR BETA; NCOR1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BAX GENE; BINDING SITE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CDKN1A GENE; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; CROSSING OVER; GENE REPRESSION; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; ONCOGENE; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SURVIVAL TIME; THYROID CANCER; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR GROWTH; ANIMAL; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; THYROID TUMOR;

MUS;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; MICE; MICE, KNOCKOUT; NUCLEAR RECEPTOR CO-REPRESSOR 1; SIGNAL TRANSDUCTION; THYROID HORMONE RECEPTORS BETA; THYROID NEOPLASMS;

EID: 84879476615     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067954     Document Type: Article

References (52)

1. Forrest D, Vennstrom B, (2000) Functions of thyroid hormone receptors in mice. Thyroid 10: 41-52.
2. Cheng SY, (2005) Isoform-dependent actions of thyroid hormone nuclear receptors: lessons from knockin mutant mice. Steroids 70: 450-454.
3. Cheng SY, (2000) Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev Endocr Metab Disord 1: 9-18.
4. Hollenberg AN, Forrest D, (2008) The thyroid and metabolism: the action continues. Cell Metab 8: 10-12.
5. Glass CK, Rosenfeld MG, (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14: 121-141.
6. Love JD, Gooch JT, Nagy L, Chatterjee VK, Schwabe JW, (2000) Transcriptional repression by nuclear receptors: mechanisms and role in disease. Biochem Soc Trans 28: 390-396.
7. Privalsky ML, (2004) The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol 66: 315-360.
8. Agostini M, Schoenmakers E, Mitchell C, Szatmari I, Savage D, et al. (2006) Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab 4: 303-311.
9. Weiss RE, Refetoff S, (2000) Resistance to thyroid hormone. Rev Endocr Metab Disord 1: 97-108.
10. Ferrara AM, Onigata K, Ercan O, Woodhead H, Weiss RE, et al. (2012) Homozygous thyroid hormone receptor beta-gene mutations in resistance to thyroid hormone: three new cases and review of the literature. J Clin Endocrinol Metab 97: 1328-1336.
11. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, et al. (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391: 811-814.
12. Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, et al. (2003) Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 9: 1259-1266.
13. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, et al. (2006) NCOR1 mRNA is an independent prognostic factor for breast cancer. Cancer Lett 237: 123-129.
14. Abedin SA, Thorne JL, Battaglia S, Maguire O, Hornung LB, et al. (2009) Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. Carcinogenesis 30: 449-456.
15. Banwell CM, MacCartney DP, Guy M, Miles AE, Uskokovic MR, et al. (2006) Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin Cancer Res 12: 2004-2013.
16. The Cancer Genome Atlas Network, (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
17. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
18. The Cancer Genome Atlas Network, (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
19. The Cancer Genome Atlas Network, (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
20. Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, et al. (2000) Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci U S A 97: 13209-13214.
21. Parrilla R, Mixson AJ, McPherson JA, McClaskey JH, Weintraub BD, (1991) Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain. J Clin Invest 88: 2123-2130.
22. Suzuki H, Willingham MC, Cheng SY, (2002) Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 12: 963-969.
23. Furuya F, Hanover JA, Cheng SY, (2006) Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci U S A 103: 1780-1785.
24. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, et al. (2001) Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61: 6105-6111.
25. Lu C, Zhao L, Ying H, Willingham MC, Cheng SY, (2010) Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology 151: 1929-1939.
26. Ying H, Furuya F, Zhao L, Araki O, West BL, et al. (2006) Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest 116: 2972-2984.
27. Kim CS, Ying H, Willingham MC, Cheng SY, (2007) The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis 28: 932-939.
28. Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY, (2008) Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol Cell Biol 28: 4598-4608.
29. Astapova I, Lee LJ, Morales C, Tauber S, Bilban M, et al. (2008) The nuclear corepressor, NCoR, regulates thyroid hormone action in vivo. Proc Natl Acad Sci U S A 105: 19544-19549.
30. Astapova I, Vella KR, Ramadoss P, Holtz KA, Rodwin BA, et al. (2011) The nuclear receptor corepressor (NCoR) controls thyroid hormone sensitivity and the set point of the hypothalamic-pituitary-thyroid axis. Mol Endocrinol 25: 212-224.
31. Astapova I, Hollenberg AN, (2013) The in vivo role of nuclear receptor corepressors in thyroid hormone action. Biochim Biophys Acta 1830: 3876-3881.
32. Fozzatti L, Lu C, Kim DW, Park JW, Astapova I, et al. (2011) Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1). Proc Natl Acad Sci U S A 108: 17462-17467.
33. Ying H, Suzuki H, Zhao L, Willingham MC, Meltzer P, et al. (2003) Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis. Cancer Res 63: 5274-5280.
34. Fozzatti L, Lu C, Kim DW, Cheng SY, (2011) Differential recruitment of nuclear coregulators directs the isoform-dependent action of mutant thyroid hormone receptors. Mol Endocrinol 25: 908-921.
35. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, et al. (1995) p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9: 935-944.
36. Miyashita T, Reed JC, (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299.
37. Qi JS, Desai-Yajnik V, Yuan Y, Samuels HH, (1997) Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression. Mol Cell Biol 17: 7195-7207.
38. Yap N, Yu CL, Cheng SY, (1996) Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53. Proc Natl Acad Sci U S A 93: 4273-4277.
39. Furuya F, Guigon CJ, Zhao L, Lu C, Hanover JA, et al. (2007) Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling. Mol Cell Biol 27: 6116-6126.
40. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, et al. (1995) Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377: 397-404.
41. Chen JD, Evans RM, (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377: 454-457.
42. Jepsen K, Rosenfeld MG, (2002) Biological roles and mechanistic actions of co-repressor complexes. J Cell Sci 115: 689-698.
43. Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, et al. (1999) Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev 13: 3198-3208.
44. Cohen RN, Brzostek S, Kim B, Chorev M, Wondisford FE, et al. (2001) The specificity of interactions between nuclear hormone receptors and corepressors is mediated by distinct amino acid sequences within the interacting domains. Mol Endocrinol 15: 1049-1061.
45. Makowski A, Brzostek S, Cohen RN, Hollenberg AN, (2003) Determination of nuclear receptor corepressor interactions with the thyroid hormone receptor. Mol Endocrinol 17: 273-286.
46. Furuya F, Lu C, Willingham MC, Cheng SY, (2007) Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 28: 2451-2458.
47. Altmann A, Eisenhut M, Bauder-Wust U, Markert A, Askoxylakis V, et al. (2010) Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. Eur J Nucl Med Mol Imaging 37: 2286-2297.
48. Catalano MG, Pugliese M, Poli R, Bosco O, Bertieri R, et al. (2009) Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib. Oncol Rep 21: 515-521.
49. Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G, (2007) Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 14: 839-845.
50. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, et al. (2006) Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191: 465-472.
51. Yuan GB, Kuang AR, Fan Q, Yu LB, Mi YX, (2010) Combined effects of all-trans-retinoic acid and trichostatin A on the induction of differentiation of thyroid carcinoma cells. Chin J Cancer 29: 379-384.
52. Russo D, Damante G, Puxeddu E, Durante C, Filetti S, (2011) Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol 46: R73-81.